All interaction tracking will be disabled, rendering you invisible to other Pharmalicensing users and technology providers.

Stealth Mode currently OFF.

Included with Premium accounts. Add-on upgrade to Plus accounts.

Please Register or Login to save this technology and benefit from all of Pharmalicensing's features.

Save to Existing Project

Save to a New Project

HypoSpray &reg; Transdermal System

Transdermal Delivery Solutions CorpUSA

Abstract ID:

The HypoSpray platform enables delivery of most pharmaceutical active ingredients in a pleasant, easy-to-use, spray-on product with nearly instant, direct absorption into the blood system and the result is early onset of relief....

Contact Deepak Basra

Add Conversation Participants

Select participants to add to this conversation

NAME

TITLE

COMPANY

Participants

You

Subject:64886

Message

Email me a copy of this message

FULL DESCRIPTION

Broadly Enabling Technology: The HypoSpray® technology presents a paradigm shift in transdermal delivery of drugs, away from small dose – small molecule therapies and limited applications to drugs that require larger bio-available doses for efficacy. As the company’s technology can accommodate large molecules, management believes it has the potential to deliver up to 70% of the drugs listed in the Physician Pharmaceutical Guide. The platform enables delivery of most pharmaceutical active ingredients in a pleasant, easy-to-use product with nearly instant, direct, absorption into the blood system. By-passing directly into the blood compartment, the stomach and gut are protected from the effects of processing and metabolizing what is essentially a foreign substance, and virtually eliminating stomach discomfort and concerns with taking medicine with meals or avoiding certain beverages or foods. The smaller dose of drug used in the HypoSpray® formula renders any drug normally taken by mouth safer by reducing toxicity, side effects and the potential for drug interactions. Technological Integration is Proven: The flexible, broadly enabling nature of the platform technology has been proven safe and effective in several studies, which have been published in peer-reviewed journals, and have demonstrated superiority of HypoSpray® systems over the market leaders, thereby minimizing the risk of technological change, while maximizing the product’s attractiveness over existing market competition.

GO PREMIUM TO GET PATENT INFORMATION

Type of Business Relationship Sought

As the Company's products address large markets requiring deep distribution capabilities, TDSC's commercialization strategy is to enter into join ventures with corporate partners who have the capability to gain meaningful market share and product revenues. The Company intends to use the strength and skills of its partners through their established market knowledge in brand positioning, distribution, marketing, sales, and scientific resources, so that the Company can maximize its return from the delivery mechanism for these approved drugs, broadening the diversity of its revenue base.

A typical transaction would include fees for accessing and securing a license for a particular API or category, milestone payments, and royalties on sales. Co-development utilizing the companyÃ¢â‚¬â„¢s cGMP, regulatory compliance and clinical capabilities and relationships are negotiable.

While the company has licensed some applications to development partnerships, the Company retains control of out licensed opportunities in all therapeutic categories. The company will evaluate potential opportunities for collaborations on new chemical entities (NCEÃ¢â‚¬â„¢s) on a case-by-case basis with a close regard to obligations in particular therapeutic categories either established or pending.